OSIRIS THERAPEUTICS, INC. (OSIR) [Rocket]

Overview

OSIRIS THERAPEUTICS, INC. (OSIR)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
04/29/2019	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]:
04/17/2019	25-NSE	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
04/17/2019	4	FRIEDLI PETER (Director) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
04/17/2019	4	Keefer Jason (Chief Commercial Officer) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
04/17/2019	4	Danilkovitch Alla (Chief Scientific Officer) has filed a Form 4 on OSIRIS THERAPEUTICS, INC.
04/17/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/17/2019	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
Revenues	142.8	118.5	109.4	79.7	50.8	25.7	7.2	1.3
Revenue growth	20.5%	8.4%	37.2%	56.8%	97.8%	258.7%	467.2%	-97.1%
Cost of goods sold	38.1	32.7	30.7	27.0	9.9	6.9	2.4	0.5
Gross profit	104.7	85.8	78.6	52.7	40.9	18.8	4.7	0.7
Gross margin	73.3%	72.4%	71.9%	66.1%	80.6%	73.3%	66.2%	58.0%
Selling, general and administrative								7.0
Sales and marketing	67.5	61.5	59.1	56.6	36.4	13.8	2.8
Research and development	6.8	4.1	6.3	4.9	3.4	4.3	4.1	4.3
General and administrative	19.6	22.1	17.4	9.5	7.6	2.5	2.3
EBIT	9.9	-2.0	-4.1	-33.5	-7.0	-2.0	-6.4	-10.8
EBIT margin	6.9%	-1.7%	-3.7%	-42.1%	-13.7%	-7.8%	-88.7%	-853.3%
Pre-tax income	10.5	-2.6	-3.7	-35.2	-8.8	-1.6	-6.3	-10.7
Income taxes	-26.0	-1.4	0.1	0.5	0.1	-1.0	0.0	-0.8
Tax rate		53.1%				62.2%	0.6%	7.3%
Earnings from continuing ops	36.5	-1.2	-3.7	-35.8	-8.9	-0.6	-6.3	-9.9
Earnings from discontinued ops	0.4	10.0			-1.1	43.1	-5.3	24.8
Net income	36.9	8.8	-3.7	-35.8	-10.0	42.5	-11.6	14.9
Net margin	25.8%	7.4%	-3.4%	-44.9%	-19.6%	165.2%	-161.7%	1179.1%

Diluted EPS	$1.06	($0.04)	($0.11)	($1.04)	($0.26)	($0.02)	($0.19)	($0.30)
Shares outstanding (diluted)	34.6	34.5	34.5	34.4	34.3	33.3	32.9	32.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.